Correlation of HBsAg (log IU/mL) and HBV DNA (log IU/mL).

<p>(A) Abbott, (B) Diasorin, (C) Bio-Rad, (D) Roche immunoassays.</p

Temporal evolution of HBsAg and HBV DNA in five patients with persistente HBV infection.

<p>HBsAg log₁₀ IU/ml (▪ and solid line), HBV DNA (▵ and dotted line).</p

Correlation of HBsAg (log₁₀ IU/mL) and HBV DNA (log₁₀ IU/mL).

<p>(A) VHB genotype A, Abbott <i>ρ</i> = 0.44, p = 0.02; Diasorin <i>ρ</i> = 0.49, p = 0.01; Bio-Rad <i>ρ</i> = 0.46, p = 0.02; Roche <i>ρ</i> = 0.47, p = 0.02; (B) genotype D, Abbott <i>ρ</i> = 0.29, p = 0.15; Diasorin <i>ρ</i> = 0.05, p = 0.81; Bio-Rad <i>ρ</i> = 0.30, p = 0.14; Roche <i>ρ</i> = 0.38, p = 0.05.</p

Comparison of the AgHBs concentrations between Abbott and Diasorin, Bio-Rad, Roche assays.

<p>Linear regression analysis of HBsAg levels (expressed in log₁₀ IU/ml) obtained by (A) Abbott vs. Diasorin, (B) Abbott vs. Bio-Rad, Abbott vs. Roche immunoassays, and Bland-Altman plot of HBsAg level differences between (D) Abbott and Diasorin, (E, F) Abbott and Bio-Rad, (G) Abbott and Roche immunoassays. The horizontal solid lines indicate the mean titer difference values, the dashed lines represent the ±1.96-SD limits from the means, and diagonal solid lines are the linear regression lines.</p

Plots of Log₁₀ IU/ml HBV-DNA/HBsAg ratio by levels of HBV replication.

<p>Plots of Log₁₀ IU/ml HBV-DNA/HBsAg ratio by levels of HBV replication.</p

Mean estimated glomerular filtration rates during triple therapy.

<p>The median decrease of eGFR was 7.68mL/min with BOC and 8.53mL/min with TVR (<i>P</i> = ns). Seven patients were hospitalized because of acute kidney failure, six of whom were in the TVR group. No CNI overdoses were observed and all patients recovered after a saline infusion.</p

Hematological adverse events and their management during triple therapy after liver transplantation.

<p>Abbreviations: EPO: erythropoietin; Hb: hemoglobin level; NC: neutrophil count; ns: non significant; PC: platelet count; PEG-IFN: pegylated interferon; RBV: ribavirin; W: week</p><p>Hematological adverse events and their management during triple therapy after liver transplantation.</p

Virological responses during triple therapy after liver transplantation.

<p>An early virological response (EVR) was observed when the HCV viral load was undetectable at week 12. An extended virological response meant negative HCV RNA at week 4 and week 12. An EOT (end of treatment response) was achieved when HCV RNA was undetectable at 48 weeks. SVR12 and SVR 24 were defined as undetectable HCV RNA at 12 and 24 weeks after the discontinuation of antiviral therapy, respectively. Five patients discontinued triple therapy (three with TVR and two with BOC) before week 48 with undetectable HCV RNA and still achieved an SVR12 and SVR24.</p

Description of immunosuppressive therapy management.

<p>Abbreviations: CNI: calcineurin inhibitors; IS: immunosuppression; n: number; sd: standard deviation; MMF: mycophenolate mofetil; PI: protease inhibitors</p><p>Description of immunosuppressive therapy management.</p

Baseline characteristics of the study population.

<p>Abbreviations: HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; M: male; n: number; PEG-IFN: pegylated interferon</p><p>Continuous variables are expressed as mean ± standard deviation.</p